Portola Pharmaceuticals Inc (NASDAQ:PTLA) has been assigned an average rating of “Buy” from the ten research firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $43.50.

Several analysts recently weighed in on PTLA shares. William Blair reiterated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Friday, August 9th. ValuEngine downgraded shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Cowen reiterated a “buy” rating and issued a $45.00 price objective on shares of Portola Pharmaceuticals in a research report on Thursday, August 8th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 17th. Finally, Morgan Stanley set a $37.00 price objective on shares of Portola Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, August 9th.

In other Portola Pharmaceuticals news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the transaction, the director now owns 18,194 shares of the company’s stock, valued at approximately $545,820. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.50% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in PTLA. Empire Life Investments Inc. boosted its stake in shares of Portola Pharmaceuticals by 1.6% in the 2nd quarter. Empire Life Investments Inc. now owns 59,159 shares of the biopharmaceutical company’s stock valued at $1,604,000 after purchasing an additional 940 shares in the last quarter. WealthPLAN Partners LLC lifted its position in Portola Pharmaceuticals by 3.1% during the 2nd quarter. WealthPLAN Partners LLC now owns 64,879 shares of the biopharmaceutical company’s stock valued at $1,968,000 after purchasing an additional 1,921 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its position in Portola Pharmaceuticals by 81.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 14,900 shares of the biopharmaceutical company’s stock valued at $403,000 after purchasing an additional 6,710 shares during the period. United Services Automobile Association lifted its position in Portola Pharmaceuticals by 0.9% during the 2nd quarter. United Services Automobile Association now owns 124,554 shares of the biopharmaceutical company’s stock valued at $3,379,000 after purchasing an additional 1,065 shares during the period. Finally, Nuveen Asset Management LLC acquired a new position in Portola Pharmaceuticals during the 2nd quarter valued at about $6,941,000.

Shares of Portola Pharmaceuticals stock traded down $1.01 during trading hours on Friday, reaching $27.80. The company’s stock had a trading volume of 1,072,409 shares, compared to its average volume of 1,583,458. The company’s 50 day simple moving average is $27.45 and its 200 day simple moving average is $30.33. The company has a debt-to-equity ratio of 453.47, a quick ratio of 3.61 and a current ratio of 3.63. Portola Pharmaceuticals has a one year low of $14.81 and a one year high of $37.95. The stock has a market cap of $1.97 billion, a P/E ratio of -5.55 and a beta of 2.18.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.05) by $0.13. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. The company had revenue of $28.42 million for the quarter, compared to the consensus estimate of $25.42 million. During the same period last year, the firm posted ($1.61) EPS. The company’s revenue for the quarter was up 608.7% on a year-over-year basis. On average, sell-side analysts predict that Portola Pharmaceuticals will post -3.83 earnings per share for the current fiscal year.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.

Read More: Bond

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.